Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P07358
UPID:
CO8B_HUMAN
Alternative names:
Complement component 8 subunit beta
Alternative UPACC:
P07358; A1L4K7
Background:
The Complement component C8 beta chain, also known as Complement component 8 subunit beta, is a crucial part of the membrane attack complex (MAC). This complex plays a pivotal role in both innate and adaptive immune responses by forming pores in the plasma membrane of target cells, leading to cell lysis and death.
Therapeutic significance:
Complement component 8 deficiency, 2, a rare disease linked to this protein, results in increased susceptibility to severe recurrent infections by Neisseria species. Understanding the role of Complement component C8 beta chain could open doors to potential therapeutic strategies for enhancing immune defense mechanisms against bacterial pathogens.